Conditional PTEN-deficient Mice as a Prostate Cancer Chemoprevention Model |
Koike, Hiroyuki
(Department of Urology, Kinki University Faculty of Medicine)
Nozawa, Masahiro (Department of Urology, Kinki University Faculty of Medicine) De Velasco, Marco A (Department of Urology, Kinki University Faculty of Medicine) Kura, Yurie (Department of Urology, Kinki University Faculty of Medicine) Ando, Naomi (Department of Urology, Kinki University Faculty of Medicine) Fukushima, Emiko (Department of Urology, Kinki University Faculty of Medicine) Yamamoto, Yutaka (Department of Urology, Kinki University Faculty of Medicine) Hatanaka, Yuji (Department of Urology, Kinki University Faculty of Medicine) Yoshikawa, Kazuhiro (Cell Therapy Center, Aichi Medical University) Nishio, Kazuto (Department of Genome Biology, Kinki University Faculty of Medicine) Uemura, Hirotsugu (Department of Urology, Kinki University Faculty of Medicine) |
1 | Askari F, Parizi MK, Jessri M, et al (2014a). Dietary patterns in relation to prostate cancer in Iranian men: a case-control study. Asian Pac J Cancer Prev, 15, 2159-63. DOI ScienceOn |
2 | Askari F, Parizi MK, Jessri M, et al (2014b). Fruit and vegetable intake in relation to prostate cancer in Iranian men: a casecontrol study. Asian Pac J Cancer Prev, 13, 5223-7. |
3 | Daniyal M, Siddiqui ZA, Akram M, et al (2014). Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev, 15, 9575-8. DOI |
4 | Davies MA (2011). Regulation, role, and targeting of Akt in cancer. J Clin Oncol, 29, 4715-7. DOI |
5 | De Bono JS, Oudard S, Ozguroglu M, et al (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 376, 1147-54. DOI |
6 | De Velasco MA, Tanaka M, Yamamoto Y, et al (2014). Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer. Carcinogenesis, 35, 2142-53. DOI |
7 | Dong HV, Lee AH, Nga NH, et al (2014). Epidemiology and prevention of prostate cancer in Vietnam. Asian Pac J Cancer Prev, 15, 9747-51. DOI |
8 | Fizazi K, Scher HI, Molina A, et al (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 13, 983-92. DOI |
9 | Garg M, Dalela D, Goel A, et al (2014). Prevention of prostate cancer with vitamins-current perspectives. Asian Pac J Cancer Prev, 15, 1897-904. DOI ScienceOn |
10 | Ittmann M, Huang J, Radaelli E, et al (2013). Animal models of human prostate cancer: the consensus report of the New York meeting of the mouse models of human cancers consortium prostate pathology committee. Cancer Res, 73, 2718-36. DOI |
11 | Kodama T, Wakisaka M, Shimazaki J (1980). Binding of chlormadinone acetate to cytosol from human benign prostatic hypertrophy. Endocrinol Jpn, 27, 53-7. DOI |
12 | Maehama T, Dixon JE (1998). The tumor suppressor, PTEN/ MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem, 273, 13375-8. DOI |
13 | Pienta KJ, Bradley D (2006). Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res, 12, 1665-71. DOI |
14 | McCall P, Witton CJ, Grimsley S, et al (2008). Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer, 99, 1296-301. DOI |
15 | McGrowder DA, Jackson LA, Crawford TV (2012). Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev, 13, 1-13. DOI ScienceOn |
16 | Parisotto M, Metzger D (2013). Genetically engineered mouse models of prostate cancer. Mol Oncol, 7, 190-205. DOI |
17 | Saw CL, Wu TY, Paredes-Gonzalez X, et al (2011). Pharmacodynamics of fish oil: protective effects against prostate cancer in TRAMP mice fed with a high fat western diet. Asian Pac J Cancer Prev, 12, 3331-4. |
18 | Scher HI, Fizazi K, Saad F, et al (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med, 367, 1187-97. DOI |
19 | Shappell SB, Thomas GV, Roberts RL, et al (2004). Prostate pathology of genetically engineered mice: definitions and classification. the consensus report from the bar harbor meeting of the mouse models of human cancer consortium prostate pathology committee. Cancer Res, 64, 2270-305. DOI |
20 | Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. DOI |
21 | Sugiyama Y, Masumori N, Fukuta F, et al (2013). Influence of isoflavone intake and equol-producing intestinal flora on prostate cancer risk. Asian Pac J Cancer Prev, 14, 1-4. DOI ScienceOn |
22 | Zhou XF, Ding ZS, Liu NB (2013). Allium vegetables and risk of prostate cancer: evidence from 132,192 subjects. Asian Pac J Cancer Prev, 14, 4131-4. DOI ScienceOn |
23 | Tewari R, Chhabra M, Natu SM, et al (2014). Significant association of metabolic indices, lipid profile, and androgen levels with prostate cancer. Asian Pac J Cancer Prev, 15, 9841-6. DOI |
24 | Yang L, Pascal M, Wu XH (2013). Review of selenium and prostate cancer prevention. Asian Pac J Cancer Prev, 14, 2181-4. DOI ScienceOn |
25 | Yoshimoto M, Cunha IW, Coudry RA, et al (2007). FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer, 97, 678-85. DOI |
![]() |